"We present the largest study to date describing the racial and ethnic identity of American CLL patients in the era of modern therapies, and the largest study analyzing the general treatment patterns ...
Chronic lymphocytic leukemia (CLL) starts in bone marrow, the soft inner part of your bones. There are some key differences that set CLL apart from other types of leukemia, such as ALL (acute ...
Researchers conducted an analysis of 4 phase 3 trials, covering 2751 patients, to address the potential for targeted agents in younger and physically fit patients who have chronic lymphocytic leukemia ...
Micro-Raman spectroscopy, integrated with statistical analysis, discriminates CLL prognostic groups, revealing biochemical heterogeneity beyond conventional molecular markers. The method identifies ...
Network meta-analysis of progression free survival in the treatment of relapsed or refractory chronic lymphocytic leukemia. This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting I. This ...
Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) are types of slow-growing cancers that affect a type of white blood cell called a lymphocyte. Lymphocytes are cells that help ...
A phase Ib/II study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor (BCL-2i), in patients (pts) with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (R/R CLL/SLL).
—A study of 1230 individuals with chronic lymphocytic leukemia and high-count monoclonal B-cell lymphocytosis demonstrated that patients with wild type TP53 had longer time to first treatment and ...
Test detects genetic abnormalities to aid in the prediction of chronic lymphocytic leukemia patient survival. Abbott received 510k clearance for an in vitro diagnostic test to aid in determining the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback